Updated Aug 7 at 11:20am ET.
Follow Eli Lilly to never miss an important update.
Morgan Stanley raised its price target for the company to 1,419 dollars, up from 1,347 dollars. This new target is about 19 percent higher than where the stock is currently trading.
The move follows a strong quarterly report where the company showed it is successfully meeting the high demand for its weight-loss treatments. This higher target reflects confidence that the company can continue to grow its earnings as it expands its manufacturing capacity.
Source: Morgan Stanley
BMO Capital set a new price target of 1,400 dollars for the stock. This target suggests the firm sees about 17 percent more room for the stock to rise from its current levels.
This call aligns with the broader view that the company's lead in the metabolic drug market is widening. Analysts are increasingly focused on how the shift toward oral pills will simplify the supply chain and help the company reach more patients.
Source: BMO Capital
Lilly reported a standout quarter with revenue jumping 48 percent to about 23 billion dollars, well ahead of the 20.7 billion dollars analysts expected. The growth was almost entirely driven by Mounjaro and Zepbound, the company's leading treatments for diabetes and weight loss. Profits also came in much higher than expected at $8.38 per share, compared to the $6.17 forecast.
The company raised its full-year sales outlook by 2 billion dollars at the midpoint, now expecting up to 87 billion dollars for 2026. This confidence suggests that Lilly is successfully navigating the manufacturing bottlenecks that have previously limited how much drug it could get to patients. For long-term owners, the story remains the same: Lilly owns the most sought-after products in pharma and is successfully scaling up to meet that demand.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Lilly will provide its late-stage drug, olomorasib, for a clinical trial to see if it works better when paired with Amplia's own treatment. This study focuses on a specific type of lung cancer that often becomes resistant to current therapies. While this is a small step in the broad oncology pipeline, it shows Lilly is actively looking for ways to expand the use of its newer cancer drugs through partnerships.
Source: GlobeNewsWire
The FDA granted Breakthrough Therapy designation to olomorasib for patients with a specific mutation in advanced pancreatic cancer. This status is reserved for drugs that show early signs of being a significant improvement over existing treatments for serious conditions. For Lilly, this could shorten the time it takes to get this drug to market, adding another potential growth driver outside of its core weight-loss business.
Source: PRNewsWire
Analysts raised their price targets in a flurry of activity following the company's strong second-quarter earnings report. Most analysts are bullish, with 33 of 45 rating the stock a buy and an average target price 13% above today's price.
The company has beaten profit estimates in seven of the last eight quarters. Management consistently sets a bar that the business then outruns as manufacturing capacity for its new drugs expands.
| Expectation | |
|---|---|
| EPS | $9.48 |
| Revenue | $21.65B |
